Sorrento Pharmaceuticals

August 23, 2021

Trillium gets a buyout while it's down

The latest deal over a CD47 asset has got investors wondering who could be next.

Better late than never for Boehringer in Covid-19

Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.

June 04, 2020

Here come the anti-Covid antibodies

Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.

September 13, 2018

Another must-have oncolytic virus asset for big pharma

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

October 05, 2017

Back to the future for small caps, but not all benefit

Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

August 14, 2015

Immuno-oncology collaborations enliven 2015’s dog days

July 28, 2015

Oncology latecomers put early assets in partnering frame

December 31, 2014

Pharma regulatory and development news over Christmas